NCT03333655View on ClinicalTrials.gov

Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 16, 2018

Primary Completion Date

August 4, 2022

Study Completion Date

August 4, 2022

Conditions
Neoplasms
Interventions
PROCEDURE

Biopsy

Participants who received or are receiving CPI therapy for metastatic cancer or hematologic malignancies.

Trial Locations (11)

10032

Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion, New York

31008

Clinica Universitaria de Navarra; Servicio de oncología, Pamplona

31059

Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O), Toulouse

37014

Sarah Cannon Cancer Center, Arrington

63108

Washington University School of Medicine; Dept of Medicine/Div of Medical Oncology, St Louis

94115

UCSF Comp Canc Ctr, San Francisco

02215

Dana-Farber Cancer Institute, Boston

110-744

Seoul National University Hospital; Department of Oncology, Seoul

138-736

Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology, Seoul

08035

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona

EC1M 6BQ

Barts Hospital; Institute of Cancer, London

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03333655 - Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy | Biotech Hunter | Biotech Hunter